Iovance Q3 revenue $68M (+13% QoQ), margin 43%; lifileucel NSCLC data durable

IOVANCE BIOTHERAPEUTICS, INC.

Q3 2025 product revenue ~$68M, up 13% sequentially; gross margin 43% on ~$39M cost of sales.
Cash and investments ~$307M; expected to fund operations into Q2 2027.
Full-year 2025 revenue guidance reaffirmed at $250-300M.
Lifileucel in NSCLC: ORR 26%, median DOR not reached at >25 months; IOV-LUN-202 enrollment to complete in 2026.
Amtagvi now at >80 U.S. authorized treatment centers; Health Canada approval in August 2025.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.